Kim K H, Oh E-J, Jung E-S, Park Y-J, Choi J Y, Kim D-G, Lee K Y, Kang C S
Department of Thoracic and Cardiovascular Surgery, College of Medicine, Seoul National University, Seoul, Korea.
Transplant Proc. 2006 Jun;38(5):1429-31. doi: 10.1016/j.transproceed.2006.03.032.
The aim of the present study was to identify whether the serum interferon-gamma (IFNgamma), a Th1 cytokine, or soluble CD30 (sCD30), a marker for activation of Th2 cytokine-producing T cells, predict acute cellular rejection episodes among liver graft patients. Pretransplant and posttransplant sera from 32 living donor liver transplant recipients obtained on days 1, 3, and 7 after surgery were tested for serum IFNgamma and sCD30 concentrations using commercial enzyme-linked immunosorbent assay kits. Recipients with an acute rejection episode (ARE) (n=14) displayed significantly higher IFNgamma concentrations pretransplant than did the patients with no ARE (n=18) (P<.05). The pretransplant serum levels of sCD30 were not different between the non-ARE and ARE groups. However, in comparison with the non-ARE group, who showed steadily decreasing serum sCD30 levels after transplantation, 12 among the 14 patients in the ARE group showed increasing sCD30 levels from day 1 to day 3 after transplantation (P<.05). These results suggest that the sCD30 increment during the early period after liver transplantation affects the immune response of rejection. This observation emphasizes the clinical relevance of serum sCD30, in addition to serum IFNgamma, as predictive markers for acute liver graft rejection.
本研究的目的是确定血清干扰素-γ（IFNγ）（一种Th1细胞因子）或可溶性CD30（sCD30）（一种产生Th2细胞因子的T细胞激活标志物）是否能预测肝移植患者的急性细胞排斥反应。使用商业酶联免疫吸附测定试剂盒，对32例活体供肝移植受者在术后第1、3和7天采集的移植前和移植后血清进行血清IFNγ和sCD30浓度检测。发生急性排斥反应（ARE）的受者（n = 14）移植前的IFNγ浓度显著高于未发生ARE的患者（n = 18）（P <.05）。非ARE组和ARE组移植前血清sCD30水平无差异。然而，与移植后血清sCD30水平持续下降的非ARE组相比，ARE组14例患者中有12例在移植后第1天至第3天sCD30水平升高（P <.05）。这些结果表明，肝移植后早期sCD30的增加影响排斥反应的免疫应答。这一观察结果强调了血清sCD30除血清IFNγ外，作为急性肝移植排斥反应预测标志物的临床相关性。
